Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
about
Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.Efficacy of single dose Nevirapine in reducing viral load in HIV positive mother in labour and transmission of HIV infection to new born babies as part of prevention of parent to child transmission.Safety of single-dose nevirapine for prevention of vertical transmission of human immunodeficiency virus infectionPharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmissionGerman-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008Prevention of mother-to-child transmission of HIV: treatment options.Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy and management of obstetric, anesthetic, and pediatric issues.Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.Factors affecting adherence to short-course ARV prophylaxis for preventing mother-to-child transmission of HIV in sub-Saharan Africa: a review and lessons for future elimination.Factors affecting the duration of exclusive breastfeeding among HIV-infected and -uninfected women in Lusaka, Zambia.Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood.
P2860
Q33827841-CDFB5CF7-4689-4CA0-B843-688AC1BC198DQ34466893-FBADD283-DBB7-4661-BA0F-CF0E633EAEA6Q34844210-9E733E4B-4044-460B-92A1-BDFA7EE16B2BQ35557216-C3C52828-EC50-4E14-9858-7342883DD9EBQ35598505-1B37A71D-E966-4EED-8CBA-76EC95182240Q35759201-BBB6109F-A6BB-4BC0-9253-060151535384Q35960319-B3D780F3-7BB0-49BC-B606-42A9B7185BF5Q36322136-3F01959C-8672-42B4-A2D6-3A898040A745Q36429712-68AB39D3-155D-4527-BA9D-265DC1F066AEQ36760093-9D9295D9-236A-4374-AEA5-F6EFD062FC38Q37247625-1600EBF7-FC57-42A4-845D-6AEAD6B1AD0AQ37351394-F3C1E775-E9D6-41E3-8BEE-F4CD7AC05701Q38172614-B5AD1763-2FF2-4355-8740-02F573350CDDQ46768892-AC5D88E7-9022-4343-AA64-568DEC3F998CQ46913600-DDFB5442-930B-4616-9D86-E64D29178274
P2860
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Timing of the maternal drug do ...... onatal single-dose nevirapine.
@en
Timing of the maternal drug do ...... onatal single-dose nevirapine.
@nl
type
label
Timing of the maternal drug do ...... onatal single-dose nevirapine.
@en
Timing of the maternal drug do ...... onatal single-dose nevirapine.
@nl
prefLabel
Timing of the maternal drug do ...... onatal single-dose nevirapine.
@en
Timing of the maternal drug do ...... onatal single-dose nevirapine.
@nl
P2093
P2860
P50
P1433
P1476
Timing of the maternal drug do ...... onatal single-dose nevirapine.
@en
P2093
Edward P Acosta
Grace M Aldrovandi
Jeffrey S A Stringer
Rosemary Kumwenda
Victor Mudenda
Victoria Chapman
P2860
P304
P356
10.1097/00002030-200307250-00010
P407
P577
2003-07-01T00:00:00Z